Sources Ozempic- semaglutide injection, solution [package insert]
10.1016/j.cmet.2010.04.014 332
Individual results vary by delivery route, dosing, baseline health status, and product quality.
While its lighter on electrolytes compared to some other options, its plant-based ingredients and stevia-sweetened formula make it an easy everyday go-to
These products are often compared by consumers to prescription GLP-1 medications, but they are not FDA-approved drugs, are not clinically equivalent to GLP-1 receptor agonists, and ingredient-level research differs significantly from finished-product trials
Conclusion: GLP-1 receptor agonist therapy was associated with a significantly lower risk of legal blindness and no difference in ION incidence